Source:http://linkedlifedata.com/resource/pubmed/id/10909035
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2000-12-14
|
pubmed:abstractText |
Of 494 parotid gland tumours treated in Copenhagen county (population 600,000 inhabitants) in the period 1986-95, 50 patients (34 males, 16 females) had tumours that were proven to be malignant, making an incidence of 0.62/100,000/year. The patients age ranged from 14 to 87 years, mean 64 years. According to the UICC classification system, 6 tumours (12%) were classified as stage I, 23 (46%) as stage II, 14 (28%) as stage III, and 7 (14%) as stage IV. The material included 41 primary parotid gland tumours, histologically the tumours were verified as mucoepidermoid carcinoma (n = 13), adenocarcinoma (n = 9), squamous cell carcinoma (n = 6), carcinoma ex pleomorph adenoma (n = 3), acinic cell carcinoma (n = 3), adenoid cystic carcinoma (n = 3) and other histological diagnoses (n = 4). Primary malignant lymphoma of the parotid gland was diagnosed in six tumours and the last three tumours were metastatic carcinoma. Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation. Surgical radicality was achieved in 76% and radicality was unrelated to tumour histology. Normal or nearly normal facial nerve function (HB1&2) was noted at last follow-up in 60%. Five-year crude survival for all patients was 68%. Survival was not dependent on N-classification. Patients in stage I had a better survival than did patients in stages II, III and IV. No significant difference was observed in 5-year crude survival or in the post-operative facial nerve function between the radically operated patients (n = 38) and patients with residual tumour (p = 0.27, Log-rank test), (p = 0.48, chi 2 test).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0365-5237
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
543
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
251-3
|
pubmed:dateRevised |
2008-2-13
|
pubmed:meshHeading |
pubmed-meshheading:10909035-Adolescent,
pubmed-meshheading:10909035-Adult,
pubmed-meshheading:10909035-Aged,
pubmed-meshheading:10909035-Aged, 80 and over,
pubmed-meshheading:10909035-Catchment Area (Health),
pubmed-meshheading:10909035-Combined Modality Therapy,
pubmed-meshheading:10909035-Denmark,
pubmed-meshheading:10909035-Female,
pubmed-meshheading:10909035-Humans,
pubmed-meshheading:10909035-Male,
pubmed-meshheading:10909035-Middle Aged,
pubmed-meshheading:10909035-Neoplasm Staging,
pubmed-meshheading:10909035-Parotid Neoplasms,
pubmed-meshheading:10909035-Survival Rate,
pubmed-meshheading:10909035-Treatment Outcome
|
pubmed:year |
2000
|
pubmed:articleTitle |
Surgical outcome in malignant parotid tumours.
|
pubmed:affiliation |
Department of ORL Head and Neck Surgery, Gentofte University Hospital, Hellerup, Denmark. Charabi@dadlnet.dk
|
pubmed:publicationType |
Journal Article
|